Work

Abstract CT235: REPLOT Trial: Phase II study of repotrectinib with or without fulvestrant in patients with HR+ HER2- metastatic invasive lobular carcinoma previously treated with endocrine therapy and CDK4/6 inhibition

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct235

Authors: Jason A. Mouabbi, Amy Hammell, Shailaja Suryawanshi, Lavinia Middleton, Roland Bassett, Toni Zaayman, Livia Geoffrey, Funda Meric-Bernstam

Institutions: The University of Texas MD Anderson Cancer Center, Bristol-Myers Squibb (United States)

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821786

Cites:

Cited by: 3

Related to: 10